VXRT:OTCMKTS
백사트
US$0.56
arrow_downward
-1.12%(-0.0063) 1D
6월 12일, 오후 4시 0분 0초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoVXRT의 주요 통계 생성 중...
시가
US$0.57
고가
US$0.60
저가
US$0.55
시가총액
1.35억
평균 거래량
43.33만
거래량
29.08만
주가수익률
3.65
52주 최고가
US$0.84
52주 최저가
US$0.26
EPS
US$0.15
베타
1.10
유통 주식수
2.42억
직원 수
65
시가
US$0.57
고가
US$0.60
저가
US$0.55
시가총액
1.35억
평균 거래량
43.33만
거래량
29.08만
주가수익률
3.65
52주 최고가
US$0.84
52주 최저가
US$0.26
EPS
US$0.15
베타
1.10
유통 주식수
2.42억
직원 수
65
뉴스 기사
웹 소스 기반
Investopedia
·
1일 전
These Nvidia-Backed Firms Are Set to Join the Nasdaq 100 Soon. Their Stocks Are Surging
Investor's Business Daily
·
1시간 전
The Next Market Test; Five Stocks In Buy Areas
프로필
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
백사트에 관한 정보